Healthcare
Indoco Remedies Limited (indoco) Secures Approval for Anacipher’s Clinical and Bioanalytical Facilities in Brazil
Indoco Remedies Ltd. announces AnaCipher’s approval from ANVISA Brazil for clinical and bioanalytical facilities, enhancing its global research capabilities.
Indoco Remedies Limited (NSE: INDOCO) has announced that its Clinical Research Organisation, AnaCipher, has received approval from the National Health Surveillance Agency of Brazil (ANVISA) for both clinical and bioanalytical facilities. This approval, granted after an inspection conducted from March 30 to April 7, 2026, authorizes AnaCipher to conduct Bioavailability & Bioequivalence studies for submission to Brazil, along with associated bioanalytical support in accordance with ANVISA regulatory requirements.
Significance of the Approval
Commenting on this development, Ms. Aditi Panandikar, Managing Director, Indoco Remedies Ltd. said, “The approval reflects our CRO’s robust quality management systems, qualified scientific and clinical teams, validated analytical capabilities, and adherence to international regulatory and Good Clinical Practice standards. It reinforces our commitment to global quality standards and enhances our ability to support pharmaceutical companies in conducting studies for Brazil and expanding across Latin America.”
Strengthening Global Footprint
This approval further strengthens AnaCipher’s international regulatory footprint and reinforces its position as a trusted partner for global clinical research programmes. AnaCipher, headquartered in Hyderabad, India, provides bioequivalence and bioavailability studies, bioanalysis, clinical operations, regulatory affairs, data management, and biostatistics services to pharmaceutical companies worldwide. The CRO has been accredited by CDSCO, USFDA, WHO, EMA, UKMHRA, MoH -Oman, TPD -Canada, NMPA – China, MCC -South Africa, and MoH -Iraq.
As a fully integrated, research-oriented pharmaceutical company, Indoco Remedies Limited has a strong global presence with a turnover of US$ 175 million and a workforce of over 6000 employees, including over 300 skilled scientists and field staff. The company has 10 manufacturing facilities, supported by a state-of-the-art R&D Centre and a CRO facility, and its facilities have been approved by most regulatory authorities including USFDA and UK-MHRA.
For more details, visit www.anaciphercro.com and www.indoco.com.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Indoco Remedies Limited
Indoco Remedies Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Indoco holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at only 3.0% and profits at 0.0% CAGR. In effect, the business treads water. The stock holds at 64% of its 52-week range with RSI at 51. In other words, neither side has a clear edge right now. The stock holds up despite 3.0% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Indoco Remedies Limited.
APLLTD
Alembic Pharmaceuticals Limited (aplltd) Receives USFDA Final Approval for Valganciclovir for Oral Solution
Alembic Pharmaceuticals Limited (APLLTD) secures USFDA final approval for Valganciclovir for Oral Solution, expanding its generic drug portfolio.
Alembic Pharmaceuticals Limited (APLLTD) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Valganciclovir for Oral Solution, 50 mg/mL. This approval marks a significant milestone for Alembic as it continues to expand its generic drug portfolio. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Valcyte for Oral Solution 50 mg/mL of CHEPLAPHARM Arzneimittel GmbH (CHEPLAPHARM).
Valganciclovir for Oral Solution Indications
Valganciclovir for oral solution is indicated for: 1) treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), and 2) prevention of CMV disease in kidney, heart, or kidney-pancreas transplant patients at high risk. Refer to the label for a detailed indication and usage.
Company’s Approval Milestone
With this approval, Alembic Pharmaceuticals Limited has now secured a cumulative total of 247 ANDA approvals (227 final approvals and 20 tentative approvals) from the USFDA. This achievement underscores Alembic’s commitment to providing high-quality, affordable generic pharmaceutical products to meet global healthcare needs.
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products worldwide. The company’s state-of-the-art research and manufacturing facilities are approved by regulatory authorities of many developed countries, including the USFDA.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Alembic moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 9.5% and profits at 25.4%, and the dividend yield stands at 1.51%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alembic Pharmaceuticals Limited.
Healthcare
Morepen Laboratories Limited (morepenlab): Q2 FY27 – from Validation to Transformation
Morepen Laboratories Limited (MOREPENLAB) reports strong Q2 FY27 results with record revenue, earnings, and a new earnings scale.
Morepen Laboratories Limited (MOREPENLAB) has reported stellar Q2 FY27 results, marking a significant transformation in its business trajectory. The company has achieved record revenue and earnings, establishing a stronger earnings profile and entering a new scale of profitability.
Record Revenue and Earnings
The company’s revenue for Q2 FY27 surged to Rs. 825 Cr, up 52% year-on-year. Earnings before interest, tax, depreciation, and amortization (EBITDA) also climbed to Rs. 311 Cr, reflecting robust operational efficiency. The profit after tax (PAT) for the quarter stood at Rs. 145 Cr, showcasing a remarkable growth trajectory.
Strong Capital Efficiency
Morepen Laboratories Limited has demonstrated superior capital efficiency with a debt/equity ratio of 0.23x for Q2 FY27, down from 0.23x in FY26. The company’s receivables turnover has improved to 49 days, compared to 66 days in FY26, indicating better working capital management.
Global Expansion and Higher-Value Growth
The company’s export revenue for H1 FY27 reached Rs. 654 Cr, a staggering 122% increase year-on-year. Exports now constitute approximately 50% of the company’s total sales revenue, driven by a more global revenue mix and higher-value business segments. The share of new molecules in API revenue has grown to 25%, highlighting Morepen’s focus on innovation and higher-margin products.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Morepen Laboratories Limited
Morepen Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Morepen gains 110.3% over three months and trades near its 52-week highs. Thin margins at 7.2% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The PEG of 1.39 sits close to fair value. The stock is neither a clear buy nor obviously expensive. Buyers show up with 1.7x the volume of sellers. Moreover, they dominated on 16 of recent sessions versus 14 for sellers — a healthy accumulation pattern. The stock rises 110.3% in three months on 8.4% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Morepen Laboratories Limited.
CIPLA
Cipla Limited Q2 FY27: Revenue and Ebitda Growth Reflect Sustained Business Momentum
Cipla Limited (NSE: CIPLA) announced Q2 FY27 results with 4% sequential revenue growth, EBITDA margin up by 200 bps, and strong net cash position.
Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for the quarter ended September 30th, 2026. The business recorded highest quarterly sales with a solid growth of 12% YoY. The company delivered global revenue of INR 7,404 Cr with a sequential growth of 4% QoQ, while EBITDA margin expanded by 200 basis points QoQ to 18.7%.
One India Business
The One India business grew at a solid 12% YoY. Branded Prescription business delivered robust growth, with key therapies outpacing the market. The Trade Generics business delivered a strong double-digit QoQ growth. Consumer Health anchor brands maintained leadership positions in their respective market segments.
North America
The U.S. business posted revenue of $172 Mn during the quarter, continuing its sequential growth trajectory. Albuterol ranked No. 1 in the overall U.S. Albuterol MDI market, with a 22% market share. The business entered an exclusive partnership with Qilu Pharmaceutical for the commercialization of a Keytruda biosimilar.
One Africa
In South Africa Private Market, secondary growth was at 6.5% versus the market growth of 5.0%. The prescription business maintained its No.2 position.
As a result, Cipla Limited continues to focus on sustained growth in its core businesses, improving productivity, and strengthening its pipeline to serve patients with trusted, high-quality medicines. We expect the upcoming product pipeline to support continued performance in North America.
Source: NSE Corporate Announcement
Fundamental & Technical Analysis of Cipla Limited
Cipla Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.
Cipla moves sideways over three months, with neither buyers nor sellers taking control. The PEG of 2.77 makes it expensive versus peers. The premium needs earnings to catch up quickly. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock holds at 31% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 7.2% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Cipla Limited.
-
Computer Hardware3 days agoNetweb Technologies India Limited (netweb) Q2 FY27: Profits Exceed Full-year FY26; Revenue and PAT Up over 4 Times
-
Healthcare3 days agoOrchid Pharma Expands Exblifep into Latin America
-
Industrials3 days agoKajaria Ceramics Limited (kajariacer) Q2 FY27 Investor Update: Revenue Up 24%, Ebitda Margin at 19.5%
-
Auto Parts3 days agoLumax Auto Technologies Limited (lumaxtech) Q2 FY27: Revenue Up 35%, PAT Surges 50%
-
APOLLO3 days agoApollo Micro Systems Limited (apollo) Q2fy27 and H1fy27 Results: Revenue Surges 97% to ₹306 Cr
-
ARVIND2 days agoArvind Limited (arvind) Inaugurates State-of-the-art Garment Manufacturing Facility in Varanasi
-
MODIS3 days agoModis Navnirman Limited (modis) Q2 & H1 FY27: Revenue Up 53%, PAT Up 59%
-
Banks - Regional3 days agoIdfc First Bank Limited (idfcfirstb) Q2 FY27: PAT Up 196.5% Yoy at ₹ 1,045 Crore